PT933995E - Metodo para tratamento de lesao endotelial - Google Patents

Metodo para tratamento de lesao endotelial

Info

Publication number
PT933995E
PT933995E PT97940974T PT97940974T PT933995E PT 933995 E PT933995 E PT 933995E PT 97940974 T PT97940974 T PT 97940974T PT 97940974 T PT97940974 T PT 97940974T PT 933995 E PT933995 E PT 933995E
Authority
PT
Portugal
Prior art keywords
treatment
epo
endothelial lesion
lesion
endothelial
Prior art date
Application number
PT97940974T
Other languages
English (en)
Portuguese (pt)
Inventor
Athanasius A Anagnostou
Sigounas George
Original Assignee
Univ East Carolina
Athanasius A Anagnostou
Sigounas George
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24861777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT933995(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ East Carolina, Athanasius A Anagnostou, Sigounas George filed Critical Univ East Carolina
Publication of PT933995E publication Critical patent/PT933995E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Materials For Medical Uses (AREA)
PT97940974T 1996-09-11 1997-09-10 Metodo para tratamento de lesao endotelial PT933995E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/712,358 US20020052309A1 (en) 1996-09-11 1996-09-11 Method of treating endothelial injury

Publications (1)

Publication Number Publication Date
PT933995E true PT933995E (pt) 2005-02-28

Family

ID=24861777

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97940974T PT933995E (pt) 1996-09-11 1997-09-10 Metodo para tratamento de lesao endotelial

Country Status (11)

Country Link
US (5) US20020052309A1 (https=)
EP (1) EP0933995B8 (https=)
JP (3) JP2001503028A (https=)
CN (2) CN1113669C (https=)
AT (1) ATE282425T1 (https=)
CA (1) CA2265547C (https=)
DE (1) DE69731652T2 (https=)
DK (1) DK0933995T3 (https=)
ES (1) ES2231889T3 (https=)
PT (1) PT933995E (https=)
WO (1) WO1998010650A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
FR2786104B1 (fr) * 1998-11-25 2002-12-27 Centre Nat Rech Scient Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
AU784550B2 (en) * 1999-04-13 2006-05-04 Kenneth S. Warren Institute, Inc., The Modulation of excitable tissue function by peripherally administered erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US6171620B1 (en) 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
US6747002B2 (en) * 1999-05-11 2004-06-08 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001254625B2 (en) * 2000-05-02 2006-02-02 Action Pharma A/S Use of alpha-MSH and EPO for preventing or treating ischemic conditions
US20020061849A1 (en) * 2000-05-02 2002-05-23 Soren Nielsen Methods for treatment of diseases associated with inflammation under non-ischemic conditions
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
EP1930023A3 (en) * 2001-04-09 2008-08-06 East Carolina University Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP1459762B1 (en) * 2001-11-02 2008-07-02 Yoshiko Yasuda Use of emp9 for the prevention of proliferative organ diseases
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
BRPI0414887A (pt) * 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
EP1686979A4 (en) * 2003-11-07 2010-03-03 Jackson H M Found Military Med ACTIVATION OF HYPOXIA-INDUCIBLE GENE EXPRESSION
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
WO2005099773A1 (en) * 2004-04-05 2005-10-27 University Of Vermont And State Agricultural College Use of erythropoietin for treatment of cancer
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
RU2426174C1 (ru) * 2010-03-29 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
US9533010B2 (en) * 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
PT2970493T (pt) 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
EP4340865A4 (en) * 2021-05-18 2025-04-02 Attias, Eyal USE OF ERYTHROPOIETIN (EPO) OR ERYTHROPOIESIS STIMULATING AGENT (ESA) FOR THE TREATMENT OF OSTEOMYELITIS, BONE INFECTION AND BONE INFLAMMATION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JPH0782174A (ja) * 1993-09-17 1995-03-28 Takeda Chem Ind Ltd 抗腫瘍剤
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
JP2001520503A (ja) * 1994-12-30 2001-10-30 カイロン コーポレイション インビボにおける固形腫瘍の処置のための方法および組成物
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Also Published As

Publication number Publication date
EP0933995A4 (en) 2002-08-28
CN1235512A (zh) 1999-11-17
DK0933995T3 (da) 2005-02-14
CN1429623A (zh) 2003-07-16
US7531501B1 (en) 2009-05-12
CA2265547C (en) 2009-12-01
US5922674A (en) 1999-07-13
US20080124401A1 (en) 2008-05-29
HK1022810A1 (en) 2000-08-25
US20020052309A1 (en) 2002-05-02
DE69731652T2 (de) 2005-12-15
CA2265547A1 (en) 1998-03-19
US20090285908A1 (en) 2009-11-19
EP0933995B1 (en) 2004-11-17
DE69731652D1 (de) 2004-12-23
EP0933995B8 (en) 2005-01-19
JP2009196999A (ja) 2009-09-03
ES2231889T3 (es) 2005-05-16
ATE282425T1 (de) 2004-12-15
US7803408B2 (en) 2010-09-28
CN1113669C (zh) 2003-07-09
JP2008133305A (ja) 2008-06-12
WO1998010650A1 (en) 1998-03-19
CN1250281C (zh) 2006-04-12
EP0933995A1 (en) 1999-08-11
JP2001503028A (ja) 2001-03-06

Similar Documents

Publication Publication Date Title
PT933995E (pt) Metodo para tratamento de lesao endotelial
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
PT927150E (pt) Compostos de lipoxina e sua utilizacao no tratamento de doencas proliferativas celulares
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
ES2137554T3 (es) 2-(2-amino-3-metoxifenil)-4-oxo-4h-(1)benzopirano para el tratamiento de desordenes proliferantes.
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
MY121548A (en) Compounds and methods for the treatment of cancer
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
IL97192A0 (en) Apparatus for surgical hyperthermia treatment of tissue,preferably the prostate,the apparatus including dilation means
WO2000061141A3 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues
GB9004348D0 (en) New use of catechol derivatives and their physiologically acceptable salts and esters
DE69517302D1 (de) Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen
RU97101420A (ru) Способ лечения тонзиллита
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
MX9203715A (es) Preparciones para el tratamiento del tejido aloinjertado.